Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Aplastic anemia and substance use: National trends and associations in the United States from 1999-2023- a CDC wonder analysis

Muhammad Shaheer Bin Faheem, Sai Sushrutha Mudupula Vemula, Nafila Zeeshan et al. Nov 03, 2025 pp. 6727-6727 10.1182/blood-2025-6727

Abstract Background: In recent years, aplastic anemia has emerged as a life-threatening disease, with known links to certain medications and...

Younger donors, better outcomes: The impact of donor age in haploidentical transplantation for acute myeloid leukemia. study conducted on behalf of geth-TC

Daniel Munárriz Lorca, Estefanía Pérez López, Carlos Martín-Rodriguez et al. Nov 03, 2025 pp. 6070-6070 10.1182/blood-2025-6070

Abstract INTRODUCTION Haploidentical hematopoietic cell transplantation (haplo-HCT) using post-transplant cyclophosphami...

The clinical observation of treating autoimmune cytopenias after allogeneic hematopoietic stem cell transplantation in children by immunoinduction therapy

Sun Yuan, Bei Yan, Zhouyang Liu Nov 03, 2025 pp. 7809-7809 10.1182/blood-2025-7809

Abstract This retrospective study explored safety and efficacy of immunoinduction methods such as Immunosuppressants are reduced and discont...

Belumosudil is effective in patients with chronic graft-versus-host disease lasting more than two years: A retrospective single-center real-world study

Cheng Zhang, Na Wang, Xueling Ge et al. Nov 03, 2025 pp. 7750-7750 10.1182/blood-2025-7750

Abstract Background: As for chronic graft-versus-host disease (cGVHD), treatment options beyond traditional strategies remain limited. Belum...

Pharmacologic drugging of BCL-2 during manufacturing restores T cell fitness and enhances CART efficacy

Nada Aboelella, Ryan Park, Erting Tang et al. Nov 03, 2025 pp. 1047-1047 10.1182/blood-2025-1047

Abstract While originally developed to induce cancer cell apoptosis, venetoclax, the most clinically relevant BH3-mimetic targeting the anti...

Real-world thrombotic and survival outcomes with erythropoiesis-stimulating agents in cancer-related anemia: A propensity-matched cohort Study

Rafi Aibani, Jennifer Collins, Amir Kamran Nov 03, 2025 pp. 3132-3132 10.1182/blood-2025-3132

Abstract Background: Erythropoiesis stimulating agents (ESAs) are frequently used to manage cancer related anemia by increasing hemoglobin le...

Mesenchymal stem cells for treating gastrointestinal-involved steroid-refractory acute graft-versus-host disease: A multicenter, single-arm, pivotal clinical Trial

Yawei Zheng, Lu Wang, Xiaodong Mo et al. Nov 03, 2025 pp. 4237-4237 10.1182/blood-2025-4237

Abstract Background: Steroid-refractory acute graft-versus-host disease (SR-aGVHD) is the predominant cause of morbidity and mortality after...

Pathogenesis on dysregulated blood glucose homeostasis in severe hand-foot-mouth disease mouse model

Qingqing Yang, Zhihua Tian, Yaozhong Zhang et al. Nov 03, 2025 pp. 1205-1205 10.1182/blood-2025-1205

Abstract Background Hand, foot, and mouth disease (HFMD) is a common infectious disease among children under five years old, with large-scal...

Mapping out the impact of MAP kinase in primary myelofibrosis

Samuel Reynolds, Andrew Kuykendall, David Sallman et al. Nov 03, 2025 pp. 3812-3812 10.1182/blood-2025-3812

Abstract Introduction Primary myelofibrosis (MF) is a genetically diverse myeloproliferative neoplasm (MPN) that is often driven by somatic m...

Mecom gene network drives chemotherapy resistance in high-risk acute myeloid leukemia

Sanjana Shah, Travis Fleming, Richard Voit et al. Nov 03, 2025 pp. 3278-3278 10.1182/blood-2025-3278

Abstract Background: Despite recent advances in targeted chemotherapies for acute myeloid leukemia (AML), treatment of relapsed and refractor...

Multilayer profiling of MRD in patients with relapsed/refractory CLL treated with venetoclax-based regimens in a real-world setting

Ilaria Romano, Alessio Bruscaggin, Georg Stussi et al. Nov 03, 2025 pp. 3901-3901 10.1182/blood-2025-3901

Abstract Background Undetectable minimal residual disease (uMRD) is a strong prognostic factor for progression-free survival (PFS) in venetoc...

primary analysis of the smart stop trial: Lenalidomide, tafasitamab, rituximab, and acalabrutinib alone and with combination chemotherapy in newly diagnosed diffuse large B-cell lymphoma

Jason Westin, Luis Fayad, Raphael Steiner et al. Nov 03, 2025 pp. 477-477 10.1182/blood-2025-477

Abstract Background: First-line therapy for newly diagnosed large B-cell lymphoma (LBCL) has remained chemotherapy-based for nearly five dec...

Venetoclax plus inotuzumab ozogamicin for relapsed and refractory ALL: Results of a phase I trial

Marlise Luskin, Julia Keating, Benjamin Frost et al. Nov 03, 2025 pp. 645-645 10.1182/blood-2025-645

Abstract Introduction: Inotuzumab ozogamicin (INO), an anti-CD22 antibody-drug conjugate, can induce a complete remission (CR) in >80...

Phase I study of NPB5005-V283 in patients with relapsed/refractory multiple myeloma

Wanyan Ouyang, William Comrie, Shiwei Jin et al. Nov 03, 2025 pp. 2295-2295 10.1182/blood-2025-2295

Abstract Background: Chimeric antigen receptor (CAR)-T cell therapies have produced durable antitumor response for the treatment of relapsed...

Automated classification of acute lymphoblastic leukemia in peripheral blood smears using a convoluted neural network, ResNet18 model

Harshitha Jagarlamudi, Ramya Elangovan, Jansi Sethuraj et al. Nov 03, 2025 pp. 4559-4559 10.1182/blood-2025-4559

Abstract Background Acute lymphoblastic leukemia (ALL) is the most prevalent malignancy in children and remains a therapeutic challenge in a...

Real-world insights into multiple myeloma management: An analysis of EHR-derived data in the UK and Germany

Christoph Buhl, Harlan Pittell, Arun Sujenthiran et al. Nov 03, 2025 pp. 8146-8146 10.1182/blood-2025-8146

Abstract Background: Multiple myeloma (MM) is a heterogeneous hematologic malignancy with significant variability in treatment approaches ac...

Comparison of PICC lines vs. tunneled catheters (Hickman/Portacaths) in stem cell transplantation: A 4 year retrospective analysis of infection rates, complications, and cost-effectiveness

Shyla Sen, Santanu Sen Nov 03, 2025 pp. 7739-7739 10.1182/blood-2025-7739

Abstract Background: Central venous catheters (CVCs) are essential for stem cell transplantation (SCT), with tunnelled c...

Glucocorticoid metabolizing enzymes predict initial glucocorticoid sensitivity in childhood ALL

Shuji Sai, Masataka Hasegawa, Shinsuke Hirabayashi et al. Nov 03, 2025 pp. 6877-6877 10.1182/blood-2025-6877

Abstract Introduction Synthetic glucocorticoids (GC) are crucial first-line treatment for childhood acute lymphoblastic leukemia (ALL). The...

Cytokine signatures in immune thrombocytopenia across clinical stages

Carlos Chavez-Trillo, Katya Unzueta-Villalobos, Pavel Davizon-Castillo et al. Nov 03, 2025 pp. 6577-6577 10.1182/blood-2025-6577

Abstract Immune Thrombocytopenia (ITP) is an autoimmune disorder marked by decreased platelet counts due to accelerated destruction and/or i...

Sickle cell disease trials redefined: Toward unified clinical endpoints through international consensus

Mohamed Yassin, Nirmish Shah, Andrew Campbell et al. Nov 03, 2025 pp. 1166-1166 10.1182/blood-2025-1166

Abstract Introduction Despite significant progress in the treatment of sickle cell disease (SCD), many clinical trials (especially recent ph...

Supportive care alone is effective for managing low-grade CRS in multiple myeloma patients treated with bispecific antibodies

Victoria Nachar, Iman Ahmed, Matthew Pianko et al. Nov 03, 2025 pp. 4579-4579 10.1182/blood-2025-4579

Abstract Introduction: Patients with relapsed/refractory multiple myeloma (RRMM) who receive BCMA or GPRC5D-directed bispecific antibodies (...

Toward ‘n of one’ gene therapies: Scalable ex vivo adenine base editing via lipid nanoparticles in a sickle cell disease model

Sarah Cotteta, Omar Banda, Friederike Herbst-Nowrouzi et al. Nov 03, 2025 pp. 7835-7835 10.1182/blood-2025-7835

Abstract Sickle cell disease (SCD) affects millions globally and results from a β-globin gene mutation causing abnormal hemoglobin and rigid...

Stroke in adults with sickle cell disease: Outcomes of a non-HbS-targeted combined hydroxyurea and manual exchange transfusion strategy

Mohammed Alkadi, Kefah Al Gadeeb, Fatimah Alhammaqi et al. Nov 03, 2025 pp. 6527-6527 10.1182/blood-2025-6527

Abstract ‏Background: ‏Ischemic stroke is a serious complication of sickle cell disease (SCD). While most secondary prev...

Feasibility and acceptability of point of care lung ultrasound for identification of acute chest syndrome in an inpatient pediatric hematology unit

Thomas Carroll Fisher-Heath, Benjamin Nti, Seethal Jacob Nov 03, 2025 pp. 4375-4375 10.1182/blood-2025-4375

Abstract Background: Acute chest syndrome (ACS) is a potentially life-threatening complication of sickle cell disease (SCD). Diagnosis is cu...

Efficacy and safety of zanubrutinib, rituximab, and venetoclax combination regimen in previously untreated follicular lymphoma: A Phase II trial from the bbc study

Chunmeng Wang, Zhengyuan Han, Jinhong Shi et al. Nov 03, 2025 pp. 7108-7108 10.1182/blood-2025-7108

Abstract Background: Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma. BCL-2 protein overexpression is observed in...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page